Hubbry Logo
PapillomaviridaePapillomaviridaeMain
Open search
Papillomaviridae
Community hub
Papillomaviridae
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Papillomaviridae
Papillomaviridae
from Wikipedia
Papillomaviridae
Electron micrograph of papillomavirus, scale bar 70 nm
Virus classification Edit this classification
(unranked): Virus
Realm: Monodnaviria
Kingdom: Shotokuvirae
Phylum: Cossaviricota
Class: Papovaviricetes
Order: Zurhausenvirales
Family: Papillomaviridae
Subfamilies and genera

See text

Papillomaviridae is a family of non-enveloped double-stranded DNA viruses whose members are known as papillomaviruses.[1] Several hundred species of papillomaviruses, traditionally referred to as "types",[2] have been identified infecting all carefully inspected mammals,[2] but also other vertebrates such as birds, snakes, turtles and fish.[3][4][5] Infection by most papillomavirus types, depending on the type, is either asymptomatic (e.g. most Beta-PVs) or causes small benign tumors, known as papillomas or warts (e.g. human papillomavirus 1, HPV6 or HPV11). Papillomas caused by some types, however, such as human papillomaviruses 16 and 18, carry a risk of becoming cancerous.[6]

Papillomaviruses are usually considered as highly host- and tissue-tropic, and are thought to rarely be transmitted between species.[7] Papillomaviruses replicate exclusively in the basal layer of the body surface tissues. All known papillomavirus types infect a particular body surface,[2] typically the skin or mucosal epithelium of the genitals, anus, mouth, or airways.[8] For example, human papillomavirus (HPV) type 1 tends to infect the soles of the feet, and HPV type 2 the palms of the hands, where they may cause warts. Additionally, there are descriptions of the presence of papillomavirus DNA in the blood and in the peripheral blood mononuclear cells.

Papillomaviruses were first identified in the early 20th century, when it was shown that skin warts, or papillomas, could be transmitted between individuals by a filterable infectious agent. In 1935 Francis Peyton Rous, who had previously demonstrated the existence of a cancer-causing sarcoma virus in chickens, went on to show that a papillomavirus could cause skin cancer in infected rabbits. This was the first demonstration that a virus could cause cancer in mammals.

Taxonomy of papillomaviruses

[edit]
Selected papillomavirus types

There are over 100 species of papillomavirus recognised,[9] though the ICTV officially recognizes a smaller number, categorized into 53 genera, as of 2019.[10][11][12] All papillomaviruses (PVs) have similar genomic organizations, and any pair of PVs contains at least five homologous genes, although the nucleotide sequence may diverge by more than 50%. Phylogenetic algorithms that permit the comparison of homologies led to phylogenetic trees that have a similar topology, independent of the gene analyzed.[13]

Phylogenetic studies strongly suggest that PVs normally evolve together with their mammalian and bird host species, but adaptive radiations, occasional zoonotic events and recombinations may also impact their diversification.[13] Their basic genomic organization appears maintained for a period exceeding 100 million years, and these sequence comparisons have laid the foundation for a PV taxonomy, which is now officially recognized by the International Committee on Taxonomy of Viruses. All PVs form the family Papillomaviridae, which is distinct from the Polyomaviridae thus eliminating the term Papovaviridae. Major branches of the phylogenetic tree of PVs are considered genera, which are identified by Greek letters. Minor branches are considered species and unite PV types that are genomically distinct without exhibiting known biological differences. This new taxonomic system does not affect the traditional identification and characterization of PV "types" and their independent isolates with minor genomic differences, referred to as "subtypes" and "variants", all of which are taxa below the level of "species".[14] Additionally, phylogenetic groupings at higher taxonomic level have been proposed.[15]

This classification may need revision in the light of the existence of papilloma–polyoma virus recombinants.[16] Additional species have also been described. Sparus aurata papillomavirus 1 has been isolated from fish.[17]

The family contains two subfamilies and 53 genera, listed hereafter (-virinae denotes subfamilies and -virus denotes genera):[18]  

Subfamily: Firstpapillomavirinae

Human papillomaviruses

[edit]

In 2014, 174 human papillomavirus types had been completely sequenced according to the International Human Papillomavirus Reference Center.[19][20] They have been divided into five genera: Alphapapillomavirus, Betapapillomavirus, Gammapapillomavirus, Mupapillomavirus and Nupapillomavirus.[19] At least 200 additional viruses have been identified that await sequencing and classification.[citation needed]

Animal papillomaviruses

[edit]
Viral papilloma in a dog

Around 280 papillomaviruses have been identified in other animals, with mammalian, avian, reptilian, and fish hosts.[21][22]

Individual papillomavirus types tend to be highly adapted to replication in a single animal species. In one study, researchers swabbed the forehead skin of a variety of zoo animals and used PCR to amplify any papillomavirus DNA that might be present.[23] Although a wide variety of papillomavirus sequences were identified in the study, the authors found little evidence for inter-species transmission. One zookeeper was found to be transiently positive for a chimpanzee-specific papillomavirus sequence. However, the authors note that the chimpanzee-specific papillomavirus sequence could have been the result of surface contamination of the zookeeper's skin, as opposed to productive infection.[citation needed]

Cottontail rabbit papillomavirus (CRPV) can cause protuberant warts in its native host, the North American rabbit genus Sylvilagus. These horn-like warts may be the original basis for the urban legends of the American antlered rabbit the Jackalope and European Wolpertinger.[24] European domestic rabbits (genus Oryctolagus) can be transiently infected with CRPV in a laboratory setting. However, since European domestic rabbits do not produce infectious progeny virus, they are considered an incidental or "dead-end" host for CRPV.[25]

Inter-species transmission has also been documented for bovine papillomavirus (BPV) type 1.[26] In its natural host (cattle), BPV-1 induces large fibrous skin warts. BPV-1 infection of horses, which are an incidental host for the virus, can lead to the development of benign tumors known as sarcoids. The agricultural significance of BPV-1 spurred a successful effort to develop a vaccine against the virus.[citation needed]

A few reports have identified papillomaviruses in smaller rodents, such as Syrian hamsters, the African multimammate rat and the Eurasian harvest mouse.[27] However, there are no papillomaviruses known to be capable of infecting laboratory mice. The lack of a tractable mouse model for papillomavirus infection has been a major limitation for laboratory investigation of papillomaviruses.[citation needed]

Twenty types have been identified in seals.[22]

Four papillomaviruses are known to infect birds: Fringilla coelebs papillomavirus 1, Francolinus leucoscepus papillomavirus 1, Psittacus erithacus papillomavirus 1 and Pygoscelis adeliae papillomavirus 1.[28] All these species have a gene (E9) of unknown function, suggesting a common origin.

Evolution

[edit]

The evolution of papillomaviruses is thought to be slow compared to many other virus types, but there are no experimental measurements currently available. This is probably because the papillomavirus genome is composed of genetically stable double-stranded DNA that is replicated with high fidelity by the host cell's DNA replication machinery.[citation needed]

It is believed that papillomaviruses generally co-evolve with a particular species of host animal over many years, although there are strong evidences against the hypothesis of coevolution.[13][29] In a particularly speedy example, HPV-16 has evolved slightly as human populations have expanded across the globe and now varies in different geographic regions in a way that probably reflects the history of human migration.[30][31] Cutaneotropic HPV types are occasionally exchanged between family members during the entire lifetime, but other donors should also be considered in viral transmission.[32]

Other HPV types, such as HPV-13, vary relatively little in different human populations. In fact, the sequence of HPV-13 closely resembles a papillomavirus of bonobos (also known as pygmy chimpanzees).[33] It is not clear whether this similarity is due to recent transmission between species or because HPV-13 has simply changed very little in the six or so million years since humans and bonobos diverged.[31]

The most recent common ancestor of this group of viruses has been estimated to have existed 424 million years ago.[34]

There are five main genera infecting humans (Alpha, Beta, Gamma, Mu and Nu). The most recent common ancestor of these genera evolved 49.7 million years ago-58.5 million years ago.[35] The most recent ancestor of the gamma genus was estimated to have evolved between 45.3 million years ago and 67.5 million years ago.[citation needed]

Structure

[edit]
Papillomavirus capsid from bovine papillomavirus

Papillomaviruses are non-enveloped, meaning that the outer shell or capsid of the virus is not covered by a lipid membrane. A single viral protein, known as L1, is necessary and sufficient for formation of a 55–60 nanometer capsid composed of 72 star-shaped capsomers (see figure). Like most non-enveloped viruses, the capsid is geometrically regular and presents icosahedral symmetry. Self-assembled virus-like particles composed of L1 are the basis of a successful group of prophylactic HPV vaccines designed to elicit virus-neutralizing antibodies that protect against initial HPV infection. As such, papillomaviridæ are stable in the environment.[citation needed]

The papillomavirus genome is a double-stranded circular DNA molecule ~8,000 base pairs in length. It is packaged within the L1 shell along with cellular histone proteins, which serve to wrap and condense DNA.[citation needed]

The papillomavirus capsid also contains a viral protein known as L2, which is less abundant. Although not clear how L2 is arranged within the virion, it is known to perform several important functions, including facilitating the packaging of the viral genome into nascent virions as well as the infectious entry of the virus into new host cells. L2 is of interest as a possible target for more broadly protective HPV vaccines.

The viral capsid consists of 72 capsomeres of which 12 are five-coordinated and 60 are six-coordinated capsomeres, arranged on a T = 7d icosahedral surface lattice.[36]

Tissue specificity

[edit]

Papillomaviruses replicate exclusively in keratinocytes. Keratinocytes form the outermost layers of the skin, as well as some mucosal surfaces, such as the inside of the cheek or the walls of the vagina. These surface tissues, which are known as stratified squamous epithelia, are composed of stacked layers of flattened cells. The cell layers are formed through a process known as cellular differentiation, in which keratinocytes gradually become specialized, eventually forming a hard, crosslinked surface that prevents moisture loss and acts as a barrier against pathogens. Less-differentiated keratinocyte stem cells, replenished on the surface layer, are thought to be the initial target of productive papillomavirus infections. Subsequent steps in the viral life cycle are strictly dependent on the process of keratinocyte differentiation. As a result, papillomaviruses can only replicate in body surface tissues.[citation needed]

Life cycle

[edit]

Infectious entry

[edit]

Papillomaviruses gain access to keratinocyte stem cells through small wounds, known as microtraumas, in the skin or mucosal surface. Interactions between L1 and sulfated sugars on the cell surface promote initial attachment of the virus.[37][38] The virus is then able to get inside from the cell surface via interaction with a specific receptor, likely via the alpha-6 beta-4 integrin,[39][40] and transported to membrane-enclosed vesicles called endosomes.[41][42] The capsid protein L2 disrupts the membrane of the endosome through a cationic cell-penetrating peptide, allowing the viral genome to escape and traffic, along with L2, to the cell nucleus.[43][44][45]

Viral persistence and latency

[edit]

After successful infection of a keratinocyte, the virus expresses E1 and E2 proteins, which are for replicating and maintaining the viral DNA as a circular episome. The viral oncogenes E6 and E7 promote cell growth by inactivating the tumor suppressor proteins p53 and pRb. Keratinocyte stem cells in the epithelial basement layer can maintain papillomavirus genomes for decades.[8]

Production of progeny virus

[edit]

The current understanding is that viral DNA replication likely occurs in the G2 phase of the cell cycle and rely on recombination-dependent replication supported by DNA damage response mechanisms (activated by the E7 protein) to produce progeny viral genomes.[46] Papillomavirus genomes are sometimes integrated into the host genome, especially noticeable with oncogenic HPVs, but is not a normal part of the virus life cycle and a dead-end that eliminates the potential of viral progeny production.[46]

The expression of the viral late genes, L1 and L2, is exclusively restricted to differentiating keratinocytes in the outermost layers of the skin or mucosal surface. The increased expression of L1 and L2 is typically correlated with a dramatic increase in the number of copies of the viral genome. Since the outer layers of stratified squamous epithelia are subject to relatively limited surveillance by cells of the immune system, it is thought that this restriction of viral late gene expression represents a form of immune evasion.[citation needed]

New infectious progeny viruses are assembled in the cell nucleus. Papillomaviruses have evolved a mechanism for releasing virions into the environment. Other kinds of non-enveloped animal viruses utilize an active lytic process to kill the host cell, allowing release of progeny virus particles. Often this lytic process is associated with inflammation, which might trigger immune attack against the virus. Papillomaviruses exploit desquamation as a stealthy, non-inflammatory release mechanism.[citation needed]

Genus Host details Tissue tropism Entry details Release details Replication site Assembly site Transmission
Dyoxipapillomavirus Vertebrates None Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Omikronpapillomavirus Porpoises Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Dyodeltapapillomavirus Vertebrates None Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Omegapapillomavirus Vertebrates Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Nupapillomavirus Humans Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Dyomupapillomavirus Vertebrates None Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Dyozetapapillomavirus Vertebrates None Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Kappapapillomavirus Rabbits Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Upsilonpapillomavirus Vertebrates Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Dyoetapapillomavirus Vertebrates None Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Sigmapapillomavirus Vertebrates Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Lambdapapillomavirus Cats; dogs Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Taupapillomavirus Vertebrates Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Betapapillomavirus Humans Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Xipapillomavirus Bovines Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Dyoepsilonpapillomavirus Vertebrates None Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Thetapapillomavirus Birds Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Etapapillomavirus Birds Epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Rhopapillomavirus Vertebrates Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Dyothetapapillomavirus Vertebrates None Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Dyoomikronpapillomavirus Vertebrates None Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Gammapapillomavirus Humans Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Alphapapillomavirus Humans; monkeys Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Sex; contact
Zetapapillomavirus Horses Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Deltapapillomavirus Ruminants Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Dyolambdapapillomavirus Vertebrates None Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Dyosigmapapillomavirus Vertebrates None Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Dyorhopapillomavirus Vertebrates None Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Psipapillomavirus Vertebrates Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Dyokappapapillomavirus Vertebrates None Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Pipapillomavirus Hamsters Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Iotapapillomavirus Rodents Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Epsilonpapillomavirus Bovines Epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Phipapillomavirus Vertebrates Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Dyonupapillomavirus Vertebrates None Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Dyopipapillomavirus Vertebrates None Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Dyoiotapapillomavirus Vertebrates None Cell receptor endocytosis Lysis Nucleus Nucleus Contact
Mupapillomavirus Humans Epithelial: mucous; epithelial: skin Cell receptor endocytosis Lysis Nucleus Nucleus Contact

Association with cancer

[edit]

Although some papillomavirus types can cause cancer in the epithelial tissues they inhabit, cancer is not a typical outcome of infection. The development of papillomavirus-induced cancers typically occurs over the course of many years. Papillomaviruses have been associated with the development of cervical cancer, penile cancer[47] and oral cancers.[48] An association with vulval cancer and urothelial carcinoma with squamous differentiation in patients with neurogenic bladder has also been noted.[49][50] There are cancer causing papillomavirus genome that encodes two small proteins called E6 and E7 that mimic cancer causing oncogenes. The way they work is that they stimulate unnatural growth of cells and block their natural defenses. Also they act on many signaling proteins that control proliferation and apoptosis.[51]

Laboratory study

[edit]

The fact that the papillomavirus life cycle strictly requires keratinocyte differentiation has posed a substantial barrier to the study of papillomaviruses in the laboratory, since it has precluded the use of conventional cell lines to grow the viruses. Because infectious BPV-1 virions can be extracted from the large warts the virus induces on cattle, it has been a workhorse model papillomavirus type for many years. CRPV, rabbit oral papillomavirus (ROPV) and canine oral papillomavirus (COPV) have also been used extensively for laboratory studies. As soon as researchers discovered that these viruses cause cancer, they worked together to find a vaccine to it. Currently, the most effective way to go about it is to mimic a virus that is composed of L1 protein but lack the DNA. Basically, our immune system builds defenses against infections, but if these infections do not cause disease they can be used as a vaccine. PDB entry 6bt3 shows how antibodies surfaces attack the surface of the virus to disable it.[52]

Some sexually transmitted HPV types have been propagated using a mouse "xenograft" system, in which HPV-infected human cells are implanted into immunodeficient mice. More recently, some groups have succeeded in isolating infectious HPV-16 from human cervical lesions. However, isolation of infectious virions using this technique is arduous and the yield of infectious virus is very low.[citation needed]

The differentiation of keratinocytes can be mimicked in vitro by exposing cultured keratinocytes to an air/liquid interface. The adaptation of such "raft culture" systems to the study of papillomaviruses was a significant breakthrough for in vitro study of the viral life cycle.[53] However, raft culture systems are relatively cumbersome and the yield of infectious HPVs can be low.[54]

The development of a yeast-based system that allows stable episomal HPV replication provides a convenient, rapid and inexpensive means to study several aspects of the HPV lifecycle (Angeletti 2002). For example, E2-dependent transcription, genome amplification and efficient encapsidation of full-length HPV DNAs can be easily recreated in yeast (Angeletti 2005).

Recently, transient high-yield methods for producing HPV pseudoviruses carrying reporter genes has been developed. Although pseudoviruses are not suitable for studying certain aspects of the viral life cycle, initial studies suggest that their structure and initial infectious entry into cells is probably similar in many ways to authentic papillomaviruses.

Human papillomavirus binds to heparin molecules on the surface of the cells that it infects. Studies have shown that the crystal of isolated L1 capsomeres has the heparin chains recognized by lysines lines grooves on the surface of the virus. Also those with the antibodies show that they can block this recognition.[55]

Genetic organization and gene expression

[edit]
Genome organization of Human papillomavirus type 16

[56]

The papillomavirus genome is divided into an early region (E), encoding six open reading frames (ORF) (E1, E2, E4, E5, E6, and E7) that are expressed immediately after initial infection of a host cell, and a late region (L) encoding a major capsid protein L1 and a minor capsid protein L2. All viral ORFs are encoded on one DNA strand (see figure). This represents a dramatic difference between papillomaviruses and polyomaviruses, since the latter virus type expresses its early and late genes by bi-directional transcription of both DNA strands. This difference was a major factor in establishment of the consensus that papillomaviruses and polyomaviruses probably never shared a common ancestor, despite the striking similarities in the structures of their virions.[citation needed]

After the host cell is infected, HPV16 early promoter is activated and a polycistronic primary RNA containing all six early ORFs is transcribed. This polycistronic RNA contains three exons and two introns and undergoes active RNA splicing to generate multiple isoforms of mRNAs.[56] One of the spliced isoform RNAs, E6*I, serves as an E7 mRNA to translate E7 oncoprotein.[57] In contrast, an intron in the E6 ORF that remains intact without splicing is necessary for translation of E6 oncoprotein.[57] However, viral early transcription subjects to viral E2 regulation and high E2 levels repress the transcription. HPV genomes integrate into host genome by disruption of E2 ORF, preventing E2 repression on E6 and E7. Thus, viral genome integration into host DNA genome increases E6 and E7 expression to promote cellular proliferation and the chance of malignancy.[citation needed]

A major viral late promoter in viral early region becomes active only in differentiated cells and its activity can be highly enhanced by viral DNA replication. The late transcript is also a polycistronic RNA which contains two introns and three exons. Alternative RNA Splicing of this late transcript is essential for L1 and L2 expression and can be regulated by RNA cis-elements and host splicing factors.[56][58][59]

Technical discussion of papillomavirus gene functions

[edit]

Genes within the papillomavirus genome are usually identified after similarity with other previously identified genes. However, some spurious open reading frames might have been mistaken as genes simply after their position in the genome, and might not be true genes. This applies specially to certain E3, E4, E5 and E8 open reading frames.[citation needed]

E1

[edit]

Encodes a protein that binds to the viral origin of replication in the long control region of the viral genome. E1 uses ATP to exert a helicase activity that forces apart the DNA strands, thus preparing the viral genome for replication by cellular DNA replication factors.

E2

[edit]

The E2 protein serves as a master transcriptional regulator for viral promoters located primarily in the long control region. The protein has a transactivation domain linked by a relatively unstructured hinge region to a well-characterized DNA binding domain. E2 facilitates the binding of E1 to the viral origin of replication. E2 also utilizes a cellular protein known as Bromodomain-4 (Brd4) to tether the viral genome to cellular chromosomes.[60] This tethering to the cell's nuclear matrix ensures faithful distribution of viral genomes to each daughter cell after cell division. It is thought that E2 serves as a negative regulator of expression for the oncogenes E6 and E7 in latently HPV-infected basal layer keratinocytes. Genetic changes, such as integration of the viral DNA into a host cell chromosome, that inactivate E2 expression tend to increase the expression of the E6 and E7 oncogenes, resulting in cellular transformation and possibly further genetic destabilization.

E3

[edit]

This small putative gene exists only in a few papillomavirus types. The gene is not known to be expressed as a protein and does not appear to serve any function.

E4

[edit]

Although E4 proteins are expressed at low levels during the early phase of viral infection, expression of E4 increases dramatically during the late phase of infection. In other words, its "E" appellation may be something of a misnomer. In the case of HPV-1, E4 can account for up to 30% of the total protein at the surface of a wart.[61] The E4 protein of many papillomavirus types is thought to facilitate virion release into the environment by disrupting intermediate filaments of the keratinocyte cytoskeleton. Viral mutants incapable of expressing E4 do not support high-level replication of the viral DNA, but it is not yet clear how E4 facilitates DNA replication. E4 has also been shown to participate in arresting cells in the G2 phase of the cell cycle.

E5

[edit]

The E5 are small, very hydrophobic proteins that destabilise the function of many membrane proteins in the infected cell.[62] The E5 protein of some animal papillomavirus types (mainly bovine papillomavirus type 1) functions as an oncogene primarily by activating the cell growth-promoting signaling of platelet-derived growth factor receptors. The E5 proteins of human papillomaviruses associated to cancer, however, seem to activate the signal cascade initiated by epidermal growth factor upon ligand binding. HPV16 E5 and HPV2 E5 have also been shown to down-regulate the surface expression of major histocompatibility complex class I proteins, which may prevent the infected cell from being eliminated by killer T cells.

E6

[edit]
Structure of Sap97 PDZ3 bound to the C-terminal peptide of HPV18 E6[63]

E6 is a 151 amino-acid peptide that incorporates a type 1 motif with a consensus sequence –(T/S)-(X)-(V/I)-COOH.[64][65] It also has two zinc finger motifs.[64]

E6 is of particular interest because it appears to have multiple roles in the cell and to interact with many other proteins. Its major role, however, is to mediate the degradation of p53, a major tumor suppressor protein, reducing the cell's ability to respond to DNA damage.[66][67]

E6 has also been shown to target other cellular proteins, thereby altering several metabolic pathways. One such target is NFX1-91, which normally represses production of telomerase, a protein that allows cells to divide an unlimited number of times. When NFX1-91 is degraded by E6, telomerase levels increase, inactivating a major mechanism keeping cell growth in check.[68] Additionally, E6 can act as a transcriptional cofactor—specifically, a transcription activator—when interacting with the cellular transcription factor, E2F1/DP1.[64]

E6 can also bind to PDZ-domains, short sequences which are often found in signaling proteins. E6's structural motif allows for interaction with PDZ domains on DLG (discs large) and hDLG (Drosophila large) tumor suppressor genes.[65][69] Binding at these locations causes transformation of the DLG protein and disruption of its suppressor function. E6 proteins also interact with the MAGUK (membrane-associated guanylate kinase family) proteins. These proteins, including MAGI-1, MAGI-2, and MAGI-3 are usually structural proteins, and can help with signaling.[65][69] More significantly, they are believed to be involved with DLG's suppression activity. When E6 complexes with the PDZ domains on the MAGI proteins, it distorts their shape and thereby impedes their function. Overall, the E6 protein serves to impede normal protein activity in such a way as to allow a cell to grow and multiply at the increased rate characteristic of cancer.

Since the expression of E6 is strictly required for maintenance of a malignant phenotype in HPV-induced cancers, it is an appealing target of therapeutic HPV vaccines designed to eradicate established cervical cancer tumors.

E7

[edit]

In most papillomavirus types, the primary function of the E7 protein is to inactivate members of the pRb family of tumor suppressor proteins. Together with E6, E7 serves to prevent cell death (apoptosis) and promote cell cycle progression, thus priming the cell for replication of the viral DNA. E7 also participates in immortalization of infected cells by activating cellular telomerase. Like E6, E7 is the subject of intense research interest and is believed to exert a wide variety of other effects on infected cells. As with E6, the ongoing expression of E7 is required for survival of cancer cell lines, such as HeLa, that are derived from HPV-induced tumors.[70]

E8

[edit]

Only a few papillomavirus types encode a short protein from the E8 gene. In the case of BPV-4 (papillomavirus genus Xi), the E8 open reading frame may substitute for the E6 open reading frame, which is absent in this papillomavirus genus.[71] These E8 genes are chemically and functionally similar to the E5 genes from some human papillomaviruses, and are also called E5/E8.

L1

[edit]

L1 spontaneously self-assembles into pentameric capsomers. Purified capsomers can go on to form capsids, which are stabilized by disulfide bonds between neighboring L1 molecules. L1 capsids assembled in vitro are the basis of prophylactic vaccines against several HPV types. Compared to other papillomavirus genes, the amino acid sequences of most portions of L1 are well-conserved between types. However, the surface loops of L1 can differ substantially, even for different members of a particular papillomavirus species. This probably reflects a mechanism for evasion of neutralizing antibody responses elicited by previous papillomavirus infections.[72]

L2

[edit]

L2 exists in an oxidized state within the papillomavirus virion, with the two conserved cysteine residues forming an intramolecular disulfide bond.[73] In addition to cooperating with L1 to package the viral DNA into the virion, L2 has been shown to interact with a number of cellular proteins during the infectious entry process. After the initial binding of the virion to the cell, L2 must be cleaved by the cellular protease furin.[74] The virion is internalized, probably through a clathrin-mediated process, into an endosome, where acidic conditions are thought to lead to exposure of membrane-destabilizing portions of L2.[43] The cellular proteins beta-actin[75] and syntaxin-18[76] may also participate in L2-mediated entry events. After endosome escape, L2 and the viral genome are imported into the cell nucleus where they traffic to a sub-nuclear domain known as an ND-10 body that is rich in transcription factors.[44] Small portions of L2 are well-conserved between different papillomavirus types, and experimental vaccines targeting these conserved domains may offer protection against a broad range of HPV types.[77]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
Papillomaviridae is a family of small, non-enveloped viruses containing circular double-stranded DNA genomes ranging from 5,748 to 8,607 base pairs, which primarily infect mucosal and cutaneous epithelia in vertebrates such as mammals, birds, reptiles, and . These viruses are characterized by icosahedral s approximately 55 nm in diameter, composed of 72 pentamers of the major capsid protein L1 and a minor component of L2, with a buoyant density of 1.34–1.35 g/cm³ in cesium chloride. Members of this family, known as papillomaviruses, establish persistent infections that can lead to benign epithelial proliferations like and, for certain high-risk types, oncogenic transformations resulting in cancers. The genome of papillomaviruses is organized into three main regions: an upstream regulatory region (URR) containing the origin of replication, an early region encoding proteins involved in viral replication and host cell modulation (such as E1 for DNA helicase activity, E2 for transcriptional regulation, and E6/E7 oncoproteins that inactivate tumor suppressors p53 and pRb), and a late region encoding the structural capsid proteins L1 and L2. Typically encoding 6–9 open reading frames, the genome has an average size of about 7,500 bp and a GC content of approximately 42%, with the DNA comprising 10–13% of the virion's weight. Replication occurs in the nucleus of differentiating keratinocytes via a bidirectional theta mechanism, initiated by E1 and E2 proteins, and proceeds in three phases: initial amplification upon infection, stable maintenance at low copy number, and amplification during host cell differentiation to produce progeny virions that are released non-lytically as epithelial cells desquamate. Taxonomically, Papillomaviridae belongs to the realm , phylum Cossaviricota, class Papovaviricetes, and order Zurhausenvirales, and is divided into two subfamilies—Firstpapillomavirinae and Secondpapillomavirinae—encompassing 53 genera and 133 species as of the latest classification. Classification is primarily based on phylogenetic analysis of the L1 major capsid protein gene, with intergenus sequence identity below 60% and intersubfamily identity below 45%. The family exhibits a broad host range across vertebrates, reflecting ancient co-evolution with hosts, though human-infecting papillomaviruses (HPVs) in the genus Alphapapillomavirus are the most studied due to their medical significance. Biologically, papillomaviruses enter host cells through micro-abrasions in the , evading immune detection to establish long-term lasting months to years, with most clearing spontaneously but persistent high-risk types leading to precancerous lesions. In humans, HPV are extremely common, with nearly all sexually active individuals acquiring at least one type during their lifetime and over 42 million currently infected as of 2024. High-risk HPVs, particularly types 16 and 18, are responsible for approximately 5% of all human cancers worldwide, including nearly all cervical cancers (over 90% of cases), as well as significant portions of anal, oropharyngeal, penile, vulvar, and vaginal cancers, resulting in about 48,000 new cases annually in the United States from 2017 to 2021. Preventive measures, such as prophylactic vaccines targeting major oncogenic types, have significantly reduced rates and associated .

Taxonomy and Classification

Overall Taxonomy

The Papillomaviridae family comprises non-enveloped viruses with circular double-stranded DNA genomes, classified in the realm Monodnaviria, kingdom Shotokuvirae, phylum Cossaviricota, class Papovaviricetes, and order Zurhausenvirales. These viruses primarily infect epithelial tissues of vertebrates, with taxonomy reflecting their phylogenetic relationships derived from genome sequences. The family is subdivided into two subfamilies: Firstpapillomavirinae and Secondpapillomavirinae. As of the 2018 ICTV classification (unchanged as of 2025), Firstpapillomavirinae includes 52 genera—such as Alphapapillomavirus, Betapapillomavirus, Gammapapillomavirus, Deltapapillomavirus, and others up to Zetapapillomavirus and beyond—with 132 recognized , though databases like document additional putative types. In contrast, Secondpapillomavirinae is limited to a single , Pipapillomavirus, containing one species. Human papillomaviruses are exclusively classified under the Alphapapillomavirus. Taxonomic demarcation relies on pairwise sequence identity in the L1 (ORF), the encoding the major protein: genera are defined by less than 60% identity, while boundaries are set at less than 70% identity, supplemented by analysis of concatenated L1, E1, E2, and L2 sequences for refinement. This L1-based approach ensures consistency in grouping viruses with shared evolutionary origins. The foundational taxonomy evolved from the 2004 classification by de Villiers et al., which introduced genus-level groupings based on L1 phylogenetic trees and sequence thresholds, expanding from a single genus to multiple host-associated clades. Since then, International Committee on Taxonomy of Viruses (ICTV) standards have incorporated ongoing genomic discoveries to update species and genera. Recent proposals from 2022 onward, including one by Van Doorslaer, advocate shifting to a more explicit evolutionary basis using multi-gene phylogenies (E1, E2, L1) to address inconsistencies in host-specific groupings, such as cross-species similarities overlooked by L1 identity alone.

Human Papillomaviruses

Human papillomaviruses (HPVs) comprise over 200 distinct types identified to date, with the majority belonging to the Alphapapillomavirus within the Papillomaviridae family. These viruses are further classified based on their oncogenic potential into low-risk and high-risk groups. Low-risk HPVs, such as types 6 and 11, primarily cause benign conditions like (condylomata acuminata) and low-grade squamous intraepithelial lesions, without significant association with malignancy. In contrast, high-risk HPVs, including types 16 and 18, are strongly linked to the development of anogenital cancers, particularly , as well as oropharyngeal and anal carcinomas. Approximately 12 to 14 high-risk types have been established, such as HPV 16, 18, 31, 33, 45, 52, and 58, based on epidemiological evidence from cohort studies associating them with persistent infection and neoplastic progression. HPVs exhibit tissue-specific , broadly categorized as mucosal or cutaneous. Mucosal HPVs, predominantly alpha types like HPV 16 and 18, infect the epithelial linings of the anogenital tract, oral cavity, and respiratory mucosa, facilitating sexual transmission and association with precancerous lesions in these sites. Cutaneous HPVs, often from beta or gamma genera (e.g., HPV types 5 and 8), target keratinized , causing common or , though some alpha types can occasionally infect . This tropism influences disease presentation and , with mucosal infections driving most HPV-related cancers. Genetic diversity within HPV types is evident through variant lineages and sublineages, defined by nucleotide differences exceeding 1% in the L1 gene. For HPV16, the most prevalent high-risk type, four main lineages (A, B, C, D) exist, with the A lineage further divided into sublineages A1–A4 (European variants) and others like B1–B2 (African) and D1–D3 (North American/Asian-American), totaling nine sublineages overall; these variants show geographic distribution and varying carcinogenic risks. Recent studies from 2023–2024 have documented lineage replacement in high-risk types post-vaccination, with increases in proportions of HPV31 (+1.23%) and HPV58 (+0.51%) over 2018–2022, alongside declines in HPV33 (-0.42%) and HPV52 (-1.43%), potentially due to competitive dynamics and vaccine cross-protection. Globally, HPV infection affects approximately 80% of sexually active individuals at some point in their lives, often asymptomatically and resolving within 1–2 years, though persistent high-risk infections elevate cancer risk. Type-specific prevalence varies, with HPV16 detected in 50–60% of cases worldwide, underscoring its dominant role in oncogenesis.

Animal Papillomaviruses

Animal papillomaviruses (PVs) infect a diverse array of non-human hosts, primarily mammals but also birds and reptiles, demonstrating high host specificity while occasionally enabling . These viruses are classified within the Papillomaviridae, distributed across multiple genera, with over 400 non-human genomes annotated in as of 2025 and approximately 70-80 ICTV-recognized species across more than 40 genera. Unlike human PVs, which are confined to five genera, animal PVs span more than 40 genera, reflecting their broad phylogenetic diversity and adaptation to various epithelial tissues. The genus Deltapapillomavirus exemplifies this distribution, encompassing bovine papillomaviruses (BPVs) such as BPV-1 and BPV-2, which primarily infect and induce fibropapillomas—benign tumors involving both epithelial and mesenchymal proliferation on the skin and mucous membranes. These fibropapillomas can cause significant discomfort, secondary infections, and production losses in affected animals. In veterinary contexts, BPV infections contribute to economic impacts in cattle farming, including reduced , decreased yield from teat , and costs associated with treatment or , with global losses estimated in millions annually due to widespread prevalence in herds. Another prominent example is found in the genus Dyoiotapapillomavirus, where Equus caballus papillomavirus type 2 (EcPV2) and cross-infections by BPVs lead to equine sarcoids—mesenchymal skin tumors in that are locally invasive and resistant to therapy. Sarcoids often arise from rare interspecies transmission of BPV-1 or BPV-2 from to via contaminated wounds or fomites, highlighting limited zoonotic-like potential among animals, though human-to-animal transmission remains undocumented. In dogs, canine oral papillomavirus (COPV, or CPV-1) from the genus Lambdapapillomavirus causes benign oral papillomas, particularly in young animals, which typically regress spontaneously but can lead to feeding difficulties if extensive. The genus Kappapapillomavirus includes the cottontail rabbit papillomavirus (CRPV, or SfPV1), which infects wild rabbits and produces cutaneous papillomas that can progress to carcinomas under certain conditions, serving as a key model for PV oncogenesis in veterinary research. Overall, animal PVs play a critical role in , necessitating vaccination strategies, such as those developed against BPV for , to mitigate outbreaks and economic burdens in industries. Their study parallels human PV taxonomy by revealing conserved genomic features and host-virus co-evolution, aiding broader antiviral development.

Virological Features

Virion Structure

Papillomaviridae virions are non-enveloped particles exhibiting with a of 50-60 nm. The follows a T=7d icosahedral lattice, characterized by 72 pentameric capsomers arranged in a skewed configuration that distinguishes it from typical T=7 structures. This provides structural stability while accommodating the viral genome within a compact shell. The major capsid protein, L1, is a 55 kDa polypeptide that self-assembles into pentamers, with 72 such units forming the outer surface. Each L1 pentamer contributes to the icosahedral framework, where 60 capsomers adopt hexavalent positions and 12 occupy pentavalent sites at the vertices. The minor capsid protein, L2, resides internally and is present in approximately 70-80 copies per virion, associating closely with the L1 capsomers to facilitate genome encapsidation. The viral genome consists of a single circular double-stranded DNA molecule averaging about 7.9 kb in length, packaged at 10-13% of the virion's weight. Within the capsid, this DNA is condensed by association with cellular histones, forming nucleosome-like structures that mimic host and protect the genome during transmission. Cryo-electron microscopy (cryo-EM) studies of papillomavirus pseudovirions have revealed detailed capsid architecture, including conformational variations in L1 and the positioning of L2 beneath the L1 shell. These models, derived from high-resolution reconstructions of human papillomavirus type 16 quasivirions, highlight how L2 interacts with the inner capsid surface, contributing to the overall structural integrity observed in native particles.

Genome Organization

The genomes of viruses in the family Papillomaviridae consist of a single molecule of circular, double-stranded DNA that ranges in size from 5,748 to 8,607 , with approximately 8 kilobases (kb) being typical for mammalian papillomaviruses. This compact structure encodes all necessary viral components without introns in the majority of open reading frames (ORFs), facilitating efficient transcription as polycistronic messenger RNAs. A key feature is the non-coding long control region (LCR), also known as the upstream regulatory region, which spans about 1 kb and is positioned upstream of the early genes. The LCR serves as the primary regulatory hub, housing the (recognized by the viral E1 ), enhancer sequences, promoter elements, and binding sites for host transcription factors and the viral E2 protein. This region enables precise control of viral in a differentiation-dependent manner during . The coding portion of the genome is divided into an early of approximately 4 kb and a late of about 3 kb, separated by a short non-coding downstream of the LCR. The early contains conserved ORFs for E1 ( essential for replication), E2 (transcriptional regulator), E6 and E7 (involved in modulation), E4 (late in expression but encoded early), and E5 (present in some genera). The late encodes the structural proteins L2 (minor ) and L1 (major ), which form the icosahedral shell that packages the . These ORFs are arranged in a unidirectional manner on the , with overlapping reading frames optimizing the limited genomic space. Genomic variations occur across genera, particularly in non-mammalian papillomaviruses, which often have shorter genomes (e.g., 7,654 bp in Pygoscelis adeliae papillomavirus 2 from birds) and altered ORF configurations, such as the presence of an E9 ORF in some avian species instead of standard mammalian early genes. Accessory ORFs like E8 in certain genera (e.g., beta-papillomaviruses), where a short E8 sequence (about 38 codons) overlaps the E1 ORF and splices with E2 to form E8^E2, contributing to transcriptional repression during persistent infection.

Replication Cycle

Host Cell Entry

Papillomaviruses, including human papillomaviruses (HPVs), initiate infection of basal through attachment mediated by the major protein L1, which binds to proteoglycans (HSPGs) on the cell surface or . This primary interaction induces conformational changes in the virion, exposing additional binding sites and facilitating transfer to secondary receptors such as (particularly α6β4) and syndecans (notably syndecan-1). These secondary engagements are essential for stabilizing the virus-cell interaction and promoting subsequent internalization, with studies showing that blocking syndecan-1 reduces HPV-16 pseudovirion binding by up to 80-90%. Following attachment, the enters the host cell via an endocytic pathway that is independent of and caveolin, relying instead on tetraspanin-enriched microdomains (TEMs) such as those involving and CD151. This process directs the virion to early endosomes, as evidenced by experiments and inhibition studies using dominant-negative mutants and siRNA, which confirm no disruption to HPV-16 entry or upon or caveolin knockdown. The icosahedral structure, formed by 72 L1 pentamers encapsulating the L2 minor protein and viral genome, supports this non-canonical uptake by allowing flexible interactions with host membranes. Within late endosomes, uncoating is triggered by the acidic environment (low ), which promotes dissociation of L1 pentamers and exposure of the minor protein L2. , a host proprotein convertase, then cleaves L2 at a conserved site (typically R-X-X-R motif near the N-terminus), releasing the L2-viral DNA (vDNA) complex from the remaining components; this cleavage occurs in 25-55% of virions depending on conditions and is critical for , as mutants lacking the site show severely reduced . The process is largely independent of cyclophilins, highlighting furin's primary role in endosomal disassembly. The L2-vDNA complex undergoes retrograde trafficking via the Golgi apparatus before nuclear import, exploiting for access to the nucleus due to breakdown. L2 contains nuclear localization signals (NLS) that facilitate binding to importins and Ran-binding proteins, enabling the complex to vDNA to host mitotic and ensure delivery to nuclear promyelocytic leukemia bodies in the . This -dependent mechanism, confirmed by time-lapse imaging and knockdown studies, allows persistent genome establishment without direct nuclear pore traversal.

Genome Replication and Persistence

Upon entry into the host , the papillomavirus establishes itself as an extrachromosomal , from which initial transcription of early viral genes occurs to initiate infection. This episomal DNA localizes to promyelocytic (PML) nuclear bodies, facilitating efficient early without integration into the host during benign infections. The viral E1 and E2 proteins then drive initial amplification in a manner dependent on their binding to the viral , utilizing host cellular DNA polymerases such as α and δ, along with accessory factors like RPA and PCNA. This process establishes a stable copy number of approximately 50-100 viral genomes per infected basal , ensuring persistence without disrupting host chromosomal integrity. While detailed for HPVs, similar episomal maintenance occurs in other papillomaviruses, with copy numbers varying by host and type. Genome replication proceeds via a bidirectional mode during the maintenance phase, where the viral replicates once per in synchrony with host , primarily in the S-phase of basal epithelial cells. Unlike lytic viruses, papillomaviruses do not induce cell lysis; instead, the episomal genomes are tethered to host mitotic chromosomes by the E2 protein, promoting equitable partitioning to daughter cells during division and maintaining low-level replication over extended periods. In benign infections, this extrachromosomal state predominates, with integration events being rare and typically associated with oncogenic progression rather than routine persistence. Latency is achieved through episomal persistence in undifferentiated basal keratinocytes, where the viral genome remains dormant without triggering a full productive cycle, serving as a reservoir for long-term . Upon differentiation and migration to suprabasal layers, the genomes reactivate, amplifying to thousands of copies to support late and virion production, though this section focuses on the maintenance rather than assembly aspects. High-risk human papillomaviruses enhance persistence by evading host immunity, particularly through E5-mediated downregulation of class I (MHC-I) expression, which reduces to cytotoxic T cells and allows infected cells to avoid clearance. Additional factors, such as E6 and E7 suppression of signaling, further contribute to this immune evasion in persistent infections.

Gene Expression

Papillomaviridae exhibit a biphasic pattern of tightly linked to the differentiation state of the infected host epithelial cells. In undifferentiated basal , early genes such as E6, E7, E1, and E2 are transcribed from promoters within the long control region (LCR), ensuring initial viral establishment and . This early phase supports viral genome replication and persistence without triggering immune responses. As cells differentiate and migrate to suprabasal layers, expression shifts to late genes L1 and L2, which encode proteins essential for virion production. This temporal regulation is orchestrated by the LCR, a non-coding upstream region containing enhancer and promoter elements that respond to cues. The E2 protein plays a central role as a transcriptional regulator, binding to palindromic sequences within the LCR to modulate promoter activity. In its dimeric form, E2 acts as an activator to enhance early gene transcription, while higher concentrations or E2-E2 interactions can repress the early promoter, fine-tuning E6 and E7 expression levels to prevent excessive host cell disruption. This dual functionality allows E2 to balance with host cell viability during the early phase. Additionally, E2 influences the transition to late gene expression by suppressing early signals, thereby promoting the use of downstream late promoters. Viral transcripts are polycistronic, undergoing extensive and to generate diverse mRNA isoforms from a compact . Multiple splice donor and acceptor sites, along with polyadenylation signals, enable the production of functional proteins from overlapping reading frames, such as full-length E6 and spliced E6* variants. Cellular factors like and hnRNPs further regulate these processes, ensuring early mRNAs predominate in basal cells while late mRNAs accumulate in differentiated layers. This post-transcriptional control is critical for efficient in the stratified . Early genes E6 and E7 manipulate the host to create a conducive environment for , particularly by driving S-phase re-entry in post-mitotic differentiated cells. E7 binds and destabilizes (pRb), releasing transcription factors to promote DNA synthesis, while E6 targets for degradation, inhibiting . This sustains the host's replication machinery in non-dividing cells, amplifying viral DNA copies without completing the full . Such manipulation underscores the virus's adaptation to the epithelial differentiation gradient.

Virion Assembly and Release

In the final stages of the papillomavirus replication cycle, the major protein L1 and minor protein L2 are expressed in the nuclei of in the granular layer of the differentiated epithelium. This expression is tightly regulated and coincides with the amplification of viral genomes to high copy numbers, ensuring availability for encapsidation. L1 self-assembles into pentameric capsomers that further organize into icosahedral virus-like particles (VLPs) within the nucleus, encapsidating the replicated viral DNA. L2 associates with the chromatinized DNA prior to L1 assembly, facilitating genome recruitment through interactions mediated by E2 binding sites in the long control region (LCR), which serve as key packaging signals for DNA encapsidation. This process yields up to approximately 1,000 mature virions per productively infected cell, organized in paracrystalline arrays within the nucleus. Virus release occurs non-lytically, as virions are shed passively along with desquamating terminally differentiated from the epithelial surface, avoiding host cell and immune detection. During this egress, the capsids undergo maturation, where interpentameric bonds form between L1 proteins in the oxidizing environment of the upper epithelial layers, conferring and resistance to . These bonds also enable pseudotyping of the L1 shell with L2, enhancing for subsequent host cell entry.

Pathogenesis

Tissue Tropism

Papillomaviruses exhibit a strict for epithelial tissues, predominantly infecting squamous epithelia of cutaneous and mucosal surfaces across various host species. This specificity ensures that viral replication is tightly coupled to the stratified architecture of these tissues, where the virus establishes persistent infections without systemic spread. While most papillomaviruses are confined to epithelial cells, rare exceptions include involvement of mesenchymal tissues, such as in bovine fibropapillomas caused by types 1 and 2 (BPV-1 and BPV-2), where the virus infects subepithelial fibroblasts leading to fibroproliferative lesions. Within epithelial tissues, papillomaviruses preferentially target , initiating infection in the basal layer of the stratified . The viral genome is maintained at low copy numbers in these undifferentiated cells, with amplification and late occurring as keratinocytes differentiate and migrate toward the surface, culminating in virion assembly in the granular layer. This lifecycle dependency on keratinocyte differentiation underscores the virus's adaptation to the regenerative and desquamative nature of epithelial barriers. Tropism patterns vary by papillomavirus genus, reflecting evolutionary adaptations to specific epithelial niches. Alpha papillomaviruses primarily infect mucosal epithelia, such as those in the anogenital and oropharyngeal regions. In contrast, beta papillomaviruses target cutaneous epithelia and are associated with conditions like . Gamma papillomaviruses also favor cutaneous sites, often involving epithelia. These genus-specific preferences are influenced by factors including the expression of attachment receptors like proteoglycans, which are abundant on the surface of stratified epithelial cells and facilitate initial viral binding in these microenvironments. Entry mechanisms are adapted to epithelial integrity, typically requiring micro-abrasions to access the basal layer.

Benign Infections

Benign infections by papillomaviruses primarily manifest as non-cancerous and mucosal lesions in s and animals, driven by specific viral genotypes that induce epithelial proliferation without malignant progression. In s, cutaneous human papillomaviruses (HPVs) such as types 2 and 4 commonly cause verruca vulgaris, or common , which appear as rough, dome-shaped papules typically on the hands, fingers, or knees. These lesions are often but can lead to cosmetic concerns or minor discomfort from friction. Mucosal low-risk HPVs, particularly types 6 and 11, are responsible for over 90% of , known as condyloma acuminata, which present as soft, flesh-colored growths in the anogenital region, ranging from small bumps to larger cauliflower-like clusters that may cause itching or during intercourse. These benign lesions are generally self-limiting, with the host clearing the infection in most cases. Approximately two-thirds of common resolve spontaneously within 12-24 months through targeting viral antigens in , often without scarring. For , spontaneous regression occurs in about 20-30% of cases within 1 year, though complete viral clearance may take longer; recurrence after apparent resolution or treatment affects 20-30% of individuals, primarily due to persistent latent viral DNA in epithelial basal layers. Epidemiologically, common warts peak in prevalence among school-aged children, affecting 10-20% of those aged 10-16 years, with higher rates in whites and immunocompromised populations due to close contact in schools and shared surfaces facilitating non-sexual transmission. , the most common viral sexually transmitted infection, predominantly impact young adults aged 20-24 years, with sexual contact as the primary mode of transmission; has reduced incidence among adolescents and young women by targeting HPV types 6 and 11. In animals, papillomaviruses also cause benign proliferative diseases. Canine oral , induced by canine papillomavirus types (e.g., CPV-1), results in wart-like growths on the , , and of young dogs, which typically regress within 1-3 months via developing immunity and rarely recur. Equine sarcoids, fibroblastic skin tumors associated with cross-species infection by types 1 and 2 (BPV-1/2), affect up to 5-10% of , presenting as firm nodules or plaques on the head, limbs, or trunk; while locally invasive, they are non-metastatic and often managed surgically, with variable spontaneous resolution.

Oncogenic Associations

Certain high-risk human papillomaviruses (HPVs), particularly types 16, 18, 31, 33, 45, 52, and 58, are responsible for approximately 5% of all human cancers worldwide. These oncogenic HPVs are causally linked to nearly 100% of cervical cancers, as well as a substantial proportion of other anogenital and oropharyngeal malignancies, including about 90% of anal cancers, 70% of oropharyngeal cancers, 60% of penile cancers, and 70% of vulvar and vaginal cancers. The persistent infection with these high-risk types drives primarily in squamous epithelial cells of the , , and oropharynx, with HPV16 and HPV18 accounting for over 70% of cases across these sites. In HPV-associated cancers, the viral genome often integrates into the host cell DNA, a process that disrupts the viral E2 open reading frame (ORF) while preserving the E6 and E7 ORFs, leading to their constitutive overexpression. The E6 protein binds and degrades the tumor suppressor p53 via ubiquitin-mediated proteolysis, impairing DNA repair and apoptosis, while E7 inactivates the retinoblastoma protein (pRb), promoting uncontrolled cell cycle progression and genomic instability. This integration event is a hallmark of progression to malignancy, as it enhances E6 and E7 oncoprotein activity, which are central to the transforming potential of high-risk HPVs. Cofactors such as and significantly amplify the risk of oncogenic progression in HPV-infected individuals. introduces carcinogenic compounds that impair immune clearance of infected cells and promote viral persistence, increasing the odds of development by up to twofold among high-risk HPV carriers. , often from or , elevates susceptibility by hindering antiviral immunity, thereby heightening the attributable risk for HPV-related cancers. For specifically, the population attributable fraction of high-risk HPV infection approaches 100%, underscoring its necessity in , though cofactors modulate the progression rate. Animal models have provided key insights into papillomavirus oncogenicity, with the Shope (cottontail rabbit) papillomavirus (CRPV) serving as a classic example where cutaneous infection induces benign papillomas that progress to invasive carcinomas in up to 75% of domestic rabbits and 5% of wild cottontails, mimicking HPV-driven neoplasia.

Evolution and Phylogeny

Origins and Co-speciation

Papillomaviruses (PVs) of the family Papillomaviridae are ancient viruses, with molecular clock analyses estimating the most recent common ancestor (MRCA) of the family at approximately 424 million years ago (95% highest posterior density [HPD]: 402–446 million years ago), rooted in the Silurian period just prior to the Devonian era, the "Age of Fish." This timeline predates the emergence of mammals by over 200 million years and aligns with the early diversification of vertebrates, as evidenced by the presence of PV-like sequences in fish, reptiles, and other non-mammalian hosts. Fossil-calibrated phylogenies further support an origin linked to epithelial changes in ancestral hosts around 350 million years ago, coinciding with the rise of reptiles. The core PV genome, consisting of the minimal backbone (E1, E2, L2, L1), likely represents the ancestral configuration, with oncogenes such as E6 and E7 emerging later in the amniote lineage around 184 million years ago (95% HPD: 161–208 million years ago). Co-speciation has been a dominant force in PV evolution, characterized by strict host fidelity where viral phylogenies closely mirror those of their hosts over tens of millions of years. For instance, phylogenetic analyses of the major capsid protein L1 gene reveal parallel branching patterns between PVs and their mammalian hosts, such as in felids, where viral divergence times align with host speciation events dating back at least 10–15 million years. This congruence indicates long-term vertical transmission and co-divergence, with PVs adapting to specific epithelial niches in their hosts, as seen in primate PVs that have co-evolved for over 40 million years. However, rare interspecies transmission events have occurred, often ancient and followed by rapid adaptation; examples include host switches in beta-PVs, where rodent-associated lineages appear to have jumped to humans, contributing to the diversity of cutaneous human PVs. Such jumps are infrequent due to PVs' high species specificity, with most incongruences in host-parasite trees attributable to niche sorting rather than widespread horizontal transfer. Recent phylogenetic studies from 2023 to 2025 have highlighted selective pressures acting on the E6 and E7 oncogenes in oncogenic PV lineages, particularly within alpha-PVs like HPV16 and HPV18. Analyses using codon-based models (e.g., PAML) reveal predominantly purifying selection on these genes to maintain protein function, but with evidence of episodic positive selection at specific sites that enhance oncogenic potential, such as those modulating and pRb interactions in high-risk variants. For HPV31 and HPV33, sublineage-specific pressures were identified in E6/E7 regions, correlating with increased carcinogenicity in certain geographic populations, underscoring how evolutionary adaptation under host immune surveillance shapes oncogenic risk.

Genetic Diversity and Variants

Papillomaviruses exhibit significant genetic diversity within and across types, primarily assessed through the major capsid protein L1 gene sequence. HPV types are classified based on ≥10% nucleotide divergence in the L1 open reading frame (ORF), while intratype variants, including lineages and sublineages, show 1.0–10% and 0.5–1.0% divergence, respectively. For instance, human papillomavirus type 16 (HPV16) comprises four major lineages—A (predominantly European), B (African), C (East Asian), and D (Asian-American)—with distinct geographical distributions and varying oncogenic potentials influenced by these genetic differences. Recombination events are rare in papillomaviruses, with limited evidence suggesting they occur primarily through co-infection, though most genomic variation arises from point driven by host immune . These often accumulate in immunogenic regions like the L1 hypervariable loops, immune evasion without altering core viral functions. In cutaneous beta- and gamma-papillomaviruses, which form part of the skin virome, diversity is notably higher in healthy individuals, where over 100 genotypes have been identified as commensal, compared to diseased states; in (EV), a rare , specific beta-HPVs (e.g., HPV5 and HPV8) predominate and contribute to persistent infections and lesions due to impaired immunity. Recent studies from indicate lineage replacement in high-risk HPVs following widespread , with shifts toward non-vaccine-targeted sublineages in types like HPV31 (increased C lineage) and HPV58 (increased A2 sublineage) among vaccinated populations in . These changes, accompanied by specific mutations in L1 loops (e.g., T267A in HPV31), suggest adaptive genetic in non-vaccine types, potentially altering without immediate oncogenic shifts. By 2025, continue to monitor these dynamics, confirming increases in certain non-vaccine HPV types post- introduction.

Molecular Biology

Early Genes

The early genes of Papillomaviridae encode proteins that are expressed soon after viral infection, primarily in the basal layers of the , to establish and maintain the viral while manipulating host cell processes. These proteins orchestrate viral DNA replication, regulate transcription, and alter cellular pathways to support persistent infection. Key among them are E1, E2, E6, and E7, with additional accessory genes like , E4, E5, and E8 providing specialized functions in select papillomavirus types. The E1 protein functions as an ATP-dependent DNA helicase essential for initiating origin-specific viral genome replication. It forms hexameric complexes that bind to the viral within the upstream regulatory region, unwinding the DNA double helix to recruit host cellular replication machinery, including and . E1's activity is tightly regulated to ensure low-copy maintenance replication in undifferentiated cells, preventing excessive amplification early in . E2 serves as a multifunctional DNA-binding that dimerizes to regulate both viral and host gene . It binds to specific palindromic sequences in the viral long control region, acting as an activator or of early promoters to fine-tune E6 and E7 transcription levels. In replication, E2 recruits E1 to the origin and tethers viral episomes to host mitotic chromosomes via interaction with protein Brd4, ensuring genome segregation during . This tethering mechanism stabilizes the viral genome in dividing . The E6 protein manipulates host pathways by targeting the tumor suppressor for ubiquitin-mediated degradation through recruitment of the cellular ubiquitin ligase E6AP. This interaction forms a ternary complex where E6 bridges E6AP and , leading to polyubiquitination and proteasomal breakdown, thereby inhibiting and DNA damage responses. E6 also binds and degrades PDZ domain-containing proteins, such as MAGI-1 and DLG1, which disrupts integrity and signaling complexes to favor viral persistence. Additionally, E6 interferes with innate immune signaling by binding IRF-3 and inhibiting responses. E7 promotes cell cycle progression by binding the (pRb) with high affinity, disrupting the pRb-E2F repressive complex and releasing free transcription factors to activate S-phase genes like cyclin E and DNA polymerase α. This binding induces pRb hyperphosphorylation and eventual ubiquitin-dependent degradation, amplifying activity. In fibropapillomaviruses, such as bovine papillomavirus type 1, the E5 protein acts as an accessory oncoprotein that dimerizes and activates platelet-derived growth factor receptor β (PDGFRβ), stimulating mitogenic signaling via PI3K and MAPK pathways to enhance cell proliferation. In human papillomaviruses, E5 similarly boosts (EGFR) signaling and downregulates class I (MHC-I) expression to evade immune detection. Accessory early genes contribute to host manipulation in a type-specific manner. The E4 protein, abundant in productive infections, induces keratinocyte hyperproliferation by disrupting cytokeratin networks, facilitating viral egress from differentiated cells, and supports late-stage genome amplification by stabilizing E1 in the nucleus. E3, found in select papillomavirus types like HPV10, modulates immune responses, though its precise role remains less characterized. The E8 protein, often expressed as an E8^E2 fusion in high-risk human papillomaviruses, represses viral transcription and replication by binding E2 sites and recruiting the NCoR/SMRT-HDAC3 corepressor complex to silence promoters. These accessory proteins collectively optimize the intracellular environment for without structural contributions.

Late Genes

The late genes of Papillomaviridae encode the structural proteins L1 and L2, which are expressed in the upper layers of infected epithelial cells during the productive phase of the viral life cycle. These proteins form the icosahedral that encases the ~8 kbp circular double-stranded DNA , protecting it and facilitating transmission. L1 constitutes approximately 95% of the capsid mass, while L2 is incorporated in smaller amounts, typically 1-72 copies per virion depending on the papillomavirus type. The major protein L1 is a pentameric protein that into virus-like particles (VLPs) resembling native virions, even in the absence of L2 or genomic DNA. This property, first demonstrated for type 1 and human papillomavirus type 16 L1 expressed in insect cells, occurs spontaneously under appropriate conditions and results in empty particles with T=7d icosahedral symmetry composed of 72 pentamers. L1 contains receptor-binding domains that mediate initial attachment to host cells via heparan sulfate proteoglycans on the and cell surface, with key basic residues such as Lys54, Lys278, Lys356, and Lys361 in HPV16 contributing to this interaction. The minor protein L2 serves as a chaperone for DNA packaging, interacting with the viral through positively charged motifs at its N- and C-termini to facilitate encapsidation during nuclear assembly in terminally differentiated . L2 also contains endosomal trafficking signals, including arginine-rich motifs such as the nuclear retention (residues 296-316 in HPV16 L2: SRRTGIRYSRIGNKQTLRTRS), which enable the L2- complex to escape late endosomes, traffic through the Golgi apparatus, and reach the nucleus during infection. Post-translational modifications regulate these processes; for instance, of L2 at 62 (a conserved site across papillomaviruses) promotes efficient uncoating and delivery by facilitating endocytic processing, while L1 at sites like Thr340 supports maturation and stability. Additionally, L2 undergoes ubiquitination during entry, which aids in uncoating by targeting the L1 shell for degradation while preserving the L2-DNA complex. L1 and L2 exhibit structural conservation across Papillomaviridae genera, with L1 sharing ~50-70% identity and conserved residues (e.g., Cys175, Cys428) forming stabilizing bonds, and L2 featuring conserved functional motifs like the N-terminal cleavage site and central trafficking domains. This conservation underpins the design of broad-spectrum VLP vaccines; for example, L1 VLPs elicit type-specific neutralizing antibodies, but incorporating conserved L2 epitopes (e.g., residues 17-36) into chimeric L1/L2 VLPs induces cross-protective immunity against diverse papillomavirus types from multiple genera.

Clinical and Laboratory Aspects

Diagnostic Methods

The diagnosis of Papillomaviridae infections, particularly human papillomaviruses (HPVs), primarily relies on molecular techniques to detect viral DNA in clinical samples such as cervical swabs, biopsies, or anal lesions, as direct visualization or cytological methods alone are insufficient for confirmation. These approaches target conserved regions of the viral genome, enabling broad-spectrum detection across the family's diverse genotypes, with a focus on high-risk types like HPV-16 and HPV-18 associated with oncogenic potential. Polymerase chain reaction (PCR)-based genotyping represents the gold standard for sensitive and specific detection of papillomaviruses, amplifying the L1 open reading frame using consensus primers such as MY09/11, which allow broad detection of over 40 HPV genotypes in a single reaction. This method achieves high sensitivity, detecting as few as 10-50 viral copies per sample, and is followed by sequencing or reverse line blot hybridization for precise typing, making it suitable for both clinical diagnostics and epidemiological surveillance. Variations like PGMY09/11 primers enhance performance by reducing non-specific amplification, particularly in low-viral-load specimens from cervical cancer screening programs. Hybrid capture assays, such as the Hybrid Capture 2 (HC2) test, provide a non-PCR-based alternative for of high-risk HPV types in cervical samples, utilizing RNA-DNA hybridization to detect 13-14 oncogenic genotypes (e.g., HPV-16, -18, -31, -45) with signal amplification via . This FDA-approved method offers comparable sensitivity to PCR (around 90-95% for high-grade lesions) but is valued for its simplicity in automated platforms, enabling large-scale population-based screening without the need for . It is particularly effective in specimens, where it serves as a reflex test following abnormal Pap smears. Serological methods for detecting anti-HPV have limited clinical utility due to their type-specific nature and inability to distinguish active from past infections, as antibody responses vary by and are often transient or undetectable in mucosal sites. Enzyme-linked immunosorbent assays (ELISAs) using virus-like particles (VLPs) as antigens are primarily employed in epidemiological studies to estimate population seroprevalence, such as tracking exposure to high-risk types in trials or cohort analyses. Neutralization assays provide more specific insights into protective immunity but are not routine for . Emerging next-generation sequencing (NGS) techniques are advancing papillomavirus diagnostics by enabling high-resolution variant detection and lineage analysis beyond standard , particularly for identifying intra-type diversity in clinical and settings since 2023. Targeted NGS panels amplify and the full HPV from low-input samples, revealing sublineages and integration events with greater accuracy than traditional PCR, and have been applied in studies of viral microbiomes and persistent infections. This approach supports personalized in but remains cost-prohibitive for routine screening.

Vaccines and Therapies

Preventive strategies against papillomavirus infections primarily rely on prophylactic vaccines that target the major protein L1 to generate virus-like particles (VLPs), inducing neutralizing antibodies that prevent initial infection. The quadrivalent human papillomavirus (HPV) vaccine, , approved in 2006, protects against HPV types 6, 11, 16, and 18, which are responsible for approximately 70% of cervical cancers and 90% of . Clinical trials demonstrated approximately 90% efficacy in reducing HPV 6/11/16/18 infections and over 99% efficacy in preventing caused by these types. The nonavalent vaccine, 9, approved in 2014, extends protection to additional oncogenic types 31, 33, 45, 52, and 58, covering about 90% of cervical cancer-causing HPVs worldwide, with efficacy exceeding 90% against cervical precancers associated with these genotypes in vaccine-naive populations. Therapeutic vaccines aim to treat established infections and precancerous lesions by stimulating cellular immunity against viral oncoproteins, particularly E6 and E7 from high-risk HPVs. DNA-based vaccines like VGX-3100, which encodes optimized E6 and E7 antigens from HPV 16 and 18, have shown results in clinical trials; in a phase 2 trial of women with high-grade squamous intraepithelial lesions (HSIL), 48% achieved histopathological regression (vs. 30% placebo), and among initial responders, 91% had sustained response without recurrence at 18 months following vaccination combined with electroporation delivery. Phase 3 trials (e.g., REVEAL 1, NCT03185013; REVEAL 2, NCT03721978) met original efficacy endpoints with ~25% achieving regression and viral clearance (vs. ~10% placebo) but failed revised biomarker-stratified endpoints, leading INOVIO to cease further development in the United States in 2023. As of 2025, INOVIO's partner ApolloBio is advancing a phase 3 trial of VGX-3100 in China for treating cervical dysplasia. Other therapeutic candidates, such as the peptide vaccine PDS0101 (in phase 3 for HPV16+ oropharyngeal cancer) and mRNA-4157 combined with pembrolizumab (phase 3 for advanced HPV-associated cancers), are under investigation as of 2025. Peptide-based therapeutic vaccines targeting E6/E7 epitopes are also under investigation, often combined with adjuvants to enhance T-cell responses. For advanced HPV-associated cancers, immune checkpoint inhibitors such as pembrolizumab have been approved, demonstrating objective response rates of 12-17% in recurrent or metastatic cervical cancer by blocking PD-1/PD-L1 interactions to reinvigorate antitumor immunity. Antiviral therapies for papillomavirus infections remain limited, with no agents specifically approved for systemic HPV treatment, but , a analog originally developed for , has been used off-label for refractory cutaneous and anogenital . Intralesional or topical inhibits viral , reducing E6 and E7 expression and promoting lesion regression in 50-80% of cases, particularly in immunocompromised patients. Experimental approaches target the viral E1 , essential for HPV ; inhibitors, such as biphenylsulfonacetic acid derivatives, have demonstrated allosteric inhibition of E1 activity , blocking replication in cell-based assays without significant host cell toxicity. These E1 inhibitors remain in preclinical stages, with challenges in achieving sufficient specificity and bioavailability for clinical use. Recent advances from 2023 to 2025 have focused on developing broader-spectrum vaccines to address non-vaccine HPV types and cutaneous papillomaviruses, including beta genus PVs associated with skin cancers in immunocompromised individuals. L2-based vaccines, utilizing conserved minor protein epitopes, have shown cross-protection against diverse HPV types in preclinical models, with mRNA platforms enhancing for potential inclusion of beta PV antigens like those from HPV5. Therapeutic innovations, such as combining VGX-3100 with checkpoint inhibitors, are exploring synergistic effects in clinical settings. Globally, HPV programs have dramatically reduced prevalence; in cohorts with high coverage (e.g., >80% in adolescent girls), targeted HPV types have declined by 80-90%, averting an estimated 90% of vaccine-type infections and contributing to a 40-88% drop in cervical precancer incidence in vaccinated populations.

References

Add your contribution
Related Hubs
User Avatar
No comments yet.